Hanmi Pharmaceutical co., Ltd. (KSE:128940) will present the results of the phase I/II domestic clinical trial of HM61713 in patients with EGFR mutation positive non-small cell lung cancer at the 51st American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 29 - June 2, 2015, in Chicago, USA.
During the conference, Hanmi Pharmaceutical will participate in a session on Lung Cancer-Non-Small Cell Metastatic, and will give a poster presentation on the results of the phase I/II domestic clinical trial with 195 patients of EGFR mutation positive non-small cell lung cancer administered with HM61713.
HM61713 selectively inhibits the mutation of signal delivery substance EGFR involved in the growth of cancer cells, and is evaluated as the third-generation EGFR tyrosine kinase inhibitor (TKI) which overcomes resistance and side effects after administration with previous EGFR TKIs Iressa® and Tarceva®.
Presentation Schedule (local time)
HM61713 (HM-EMSI-101)
Updated safety and efficacy results
from I/II study of HM61713 in patients with EGFR mutation positive
non-small cell lung cancer who failed previous EGFR-tyrosine kinase
inhibitor, Poster Session, at 08:00 on Jun 1 (Mon).
Hanmi Pharmaceutical co., Ltd.
Hanmi Pharmaceutical is a
Korea-based pharmaceutical company. The Company invests over 20 percent
of its sales in R&D and has over 20 programs consisting of the novel
long acting biologics including weekly Insulin, weekly to monthly GLP-1,
and their combination for diabetes and obesity (collectively referred as
Quantum Project), the novel targeted anti-cancer drugs with improved
tolerance and safety profile and fixed-dose combination drugs. For more
detail about the company, visit http://www.hanmipharm.com
.
View source version on businesswire.com: http://www.businesswire.com/news/home/20150528005595/en/
Contacts:
Seung-woo Han / Eun-ryeong
Jang, +82 2-410-0411
Communication Team
pa@hanmi.co.kr